Trials / Completed
CompletedNCT01039480
Aspirin and Clopidogrel Resistance Study
Aspirin- and Clopidogrel-Resistance: Non-compliance and Other Contributing Factors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 82 (actual)
- Sponsor
- University Hospital, Basel, Switzerland · Academic / Other
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
Resistance to antiplatelet drugs (aspirin, clopidogrel) is a recognized phenomenon with a prevalence from 17% to 35%. Resistance as detected by in vitro tests such as Multiple Electrode Aggregometry (MEA) has been shown to predict clinical therapy failure. Resistance can be caused by clinical, cellular and pharmacogenetic factors. Non compliance is suspected to be an important contributing factor. In this study, compliance will be assured with an electronical compliance monitoring system. Factors to non response will be identified to find plausible explanations when in vitro platelet aggregation inhibition is insufficient despite assured compliance. This study will help to disclose the relationship between compliance, biomarker and clinical outcome as well as to quantify the impact of non compliance to the resistance phenomenon as measured by MEA.
Conditions
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-06-01
- Completion
- 2011-10-01
- First posted
- 2009-12-25
- Last updated
- 2012-02-09
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01039480. Inclusion in this directory is not an endorsement.